Bispecific antibodies (BsAbs) are a class of artificial proteins that are engineered to recognize two different antigens or epitopes. This capability allows them to simultaneously engage two different types of targets, such as cancer cells and immune cells, which can enhance the body's immune response against tumors or address complex diseases that require the modulation of multiple biological pathways. Bispecific antibodies represent a significant advancement in therapeutic antibody engineering and offer promising strategies for the treatment of various diseases, including cancer, autoimmune disorders, and infectious diseases. Stay curious, stay innovative. I'm Luke McLaughlin. If you would like to learn more about this topic consider reading our full length articles on www.biotechnologyreviews.com Or consider our podcast series on youtube or Spotify at our Biotechnology Reviews Channel. Our articles are also available on our linkedin newsletter Biotechnology Reviews.